Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharm-country entities : In8bio inc save search
IN8bio to Present at Upcoming Investor Conferences
Published: 2024-02-26 (Crawled : 16:00) - biospace.com/
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: 2.83%
H: 3.06%
C: 0.47%
IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma
Published: 2023-04-25 (Crawled : 14:20) - biospace.com/
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: -8.67%
H: 9.49%
C: -30.29%
inb-400 fda drug treatment designation glioblastoma
IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023
Published: 2023-04-17 (Crawled : 14:00) - biospace.com/
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: 5.66%
H: 6.37%
C: 0.9%
cd33 positive preclinical meeting program platform
IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting
Published: 2023-04-11 (Crawled : 14:00) - biospace.com/
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: 10.66%
H: 5.38%
C: 0.0%
inb-100 positive meeting trial
IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
Published: 2023-03-30 (Crawled : 22:00) - biospace.com/
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: 2.19%
H: 0.0%
C: -7.14%
update financial results
IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference
Published: 2023-02-21 (Crawled : 17:00) - biospace.com/
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: 9.59%
H: 0.0%
C: -12.62%
conference therapy
IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-08-12 (Crawled : 22:00) - biospace.com/
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: -2.02%
H: 0.52%
C: -4.64%
update results
IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022
Published: 2022-06-06 (Crawled : 20:00) - biospace.com/
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: -3.77%
H: 31.76%
C: 5.88%
inb-200 trial asco positive phase 1 glioblastoma
IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-05-12 (Crawled : 13:00) - biospace.com/
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: 3.89%
H: 3.32%
C: -1.6%
results
IN8bio to Present at May Investor and Scientific Conferences
Published: 2022-05-04 (Crawled : 13:00) - biospace.com/
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: 10.0%
H: 0.0%
C: -1.09%
IN8bio to Present at April Investor and Scientific Conferences
Published: 2022-04-05 (Crawled : 00:00) - biospace.com/
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: -2.38%
H: 9.49%
C: 4.14%
IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
Published: 2022-03-28 (Crawled : 18:00) - biospace.com/
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: 1.2%
H: 0.0%
C: -3.85%
inb-100 ongoing leukemia trial therapy t-cell phase 1
IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme
Published: 2022-01-06 (Crawled : 14:00) - biospace.com/
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: 4.66%
H: 2.34%
C: 2.34%
genetic trial cel phase 1 therapy t-cell glioblastoma
IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
Published: 2021-12-16 (Crawled : 13:30) - biospace.com/
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: 3.96%
H: 8.32%
C: -4.51%
ema ongoing leukemia trial cel stem cell phase 1 therapy t-cell
IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer
Published: 2021-11-16 (Crawled : 15:30) - biospace.com/
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: 1.58%
H: 5.02%
C: -3.82%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
IN8bio to Present Preclinical Data on the Potential for Gamma-Delta T-cell Therapy Combinations with PARP and Checkpoint Inhibitors in Solid Tumors
Published: 2021-11-11 (Crawled : 14:00) - biospace.com/
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: -3.04%
H: 7.24%
C: -1.81%
solid tumors potential therapy t-cell preclinical pre-clinical
IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Published: 2021-11-10 (Crawled : 23:00) - biospace.com/
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: 3.31%
H: 0.48%
C: -2.29%
financial results results
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.